Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC trimmed its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,571 shares of the pharmaceutical company’s stock after selling 167 shares during the period. Valeo Financial Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $2,035,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. DAVENPORT & Co LLC lifted its stake in Vertex Pharmaceuticals by 0.4% during the 2nd quarter. DAVENPORT & Co LLC now owns 226,184 shares of the pharmaceutical company’s stock valued at $100,490,000 after acquiring an additional 874 shares during the period. Simplicity Wealth LLC lifted its stake in shares of Vertex Pharmaceuticals by 133.6% in the 2nd quarter. Simplicity Wealth LLC now owns 3,035 shares of the pharmaceutical company’s stock valued at $1,351,000 after purchasing an additional 1,736 shares during the period. BridgePort Financial Solutions LLC lifted its stake in shares of Vertex Pharmaceuticals by 6.3% in the 2nd quarter. BridgePort Financial Solutions LLC now owns 843 shares of the pharmaceutical company’s stock valued at $375,000 after purchasing an additional 50 shares during the period. Strid Group LLC acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $1,113,000. Finally, Willner & Heller LLC lifted its stake in shares of Vertex Pharmaceuticals by 5.2% in the 2nd quarter. Willner & Heller LLC now owns 1,216 shares of the pharmaceutical company’s stock valued at $541,000 after purchasing an additional 60 shares during the period. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at $17,535,600. This represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald decreased their target price on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating for the company in a research note on Tuesday, August 5th. BMO Capital Markets set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the company an “outperform” rating in a research note on Tuesday, August 5th. Stifel Nicolaus decreased their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a research note on Tuesday, August 5th. Morgan Stanley set a $439.00 target price on shares of Vertex Pharmaceuticals and gave the company an “equal weight” rating in a research note on Tuesday, August 5th. Finally, Raymond James Financial assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a “market perform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $493.81.

Vertex Pharmaceuticals Stock Down 0.1%

Vertex Pharmaceuticals stock opened at $402.90 on Tuesday. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The firm has a market capitalization of $103.30 billion, a price-to-earnings ratio of 28.80 and a beta of 0.43. The company has a fifty day simple moving average of $397.96 and a 200-day simple moving average of $441.32.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. During the same quarter in the prior year, the firm earned ($12.83) earnings per share. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.